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Disease
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 Aerobic gram-negative bacteria
 At least 13 serogroups based polysaccharide capsule
 Most invasive disease caused by serogroups A, B, C, Y, and W
 Relative importance of serogroups depends on geographic location and 
other factors (e.g., age)
Neisseria meningitidis
 Organism colonizes nasopharynx
 In some persons organism enters the bloodstream and causes infection 
at distant site
 Antecedent URI may be a contributing factor
Meningococcal Disease Pathogenesis
 Incubation period 3-4 days (range 2-10 days)
 Abrupt onset of fever, meningeal symptoms, hypotension, and rash
 Fatality rate 10%-15%, up to 40% in meningococcemia
Neisseria meningitidis
Clinical Features
 Most common presentation of invasive disease
 Results from hematogenous dissemination
 Clinical findings 
– fever
– headache 
– stiff neck
Meningococcal Meningitis
 Meningococcemia
 Bloodstream infection
 May occur with or without meningitis
 Clinical findings 
– fever
– petechial or purpuric rash
– hypotension
– shock
– acute adrenal hemorrhage
– multi-organ failure
Meningococcal Sepsis
Meningococcal Disease
Meningococcal Disease
N Engl J Med. 2001;344:137
 Host Factors
– Deficiencies in the terminal common complement pathways
– Functional or anatomic asplenia
– Chronic underlying disease
– Certain genetic factors (altered genes:  mannose-binding lectin and tumor necrosis factor)
 Environmental factors 
– Household crowding
– Active and passive smoking
– Antecedent viral infection 
 Occupational (microbiologists)
Neisseria meningitidis
Risk Factors for Invasive Disease
 College Students
– Studies in 1990s – overall incidence similar to or lower than their counterparts in 
general population*
– Case control study of 50 cases and other studies in the 1990s#
• First-year college students living in residence halls at higher risk
Neisseria meningitidis
Risk Factors for Invasive Disease
*JAMA 1999;281:1906-10
#Abstracts of the 39th Meeting of the IDSA.  Philadelphia, PA: IDSA; 1999:276
Epidemiol Infect 1999;122:351–7. Clin Infect Dis 1999;29:215–6.
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United States, 1996–2015
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Abbreviations: MenACWY = quadrivalent meningococcal conjugate vaccine; MenB vaccine = serogroup B meningococcal vaccines
Source: 1996-2015 NNDSS Data
0.12 cases/100,000 
population
MenB vaccine
MenACWY vaccine
1.3 cases/100,000 
population
Year
In
cid
en
ce
 p
er
 1
00
,0
00
13
0
0.02
0.04
0.06
0.08
0.1
0.12
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
B C Y W Other
Source: National Notifiable Diseases Surveillance System (NNDSS) data with additional serogroup data from Active Bacterial Core surveillance (ABCs) and state health departments 
Trends in Meningococcal Disease Incidence by 
Serogroup – United States, 2006-2015
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Meningococcal Disease by Serogroup, All Ages –
United States, 2006-2015
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Rates of Meningococcal Disease 
(C and Y) by Age, 1999–2008
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Option 1
Dose at 11–12 years 
and booster at 16 years
Option 2
Single dose at 16 years
 Outbreaks account for  2%-3% of reported cases
 Most recent outbreaks caused by serogroup C and B 
Meningococcal Outbreaks in the United States
MMWR March 22, 2013 Recommendations and Reports / Vol. 62 / No. 2, at http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf, and
http://www.cdc.gov/meningococcal/outbreaks/index.html
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Serogroup B meningococcal disease outbreaks on 
college campuses†, 2013–2018
During 2014–2016, 31.7% of 
serogroup B cases in college students 
were outbreak-related.
State of University Year 
started
Cases 
(deaths)
Undergraduate 
population
New Jersey 2013 9 (1) 5,000
California 2013 4* 19,000
Rhode Island 2015 2 4,000
Oregon 2015 7 (1) 20,000
California 2016 2** 5,000
New Jersey 2016 2 35,000
Wisconsin 2016 3 30,000
Oregon 2016 5 25,000
Massachusetts 2017 3 30,000
Pennsylvania 2017 2 3,600
†Where CDC consulted; *1 additional associated case identified after retrospective case review; **1 additional patient with inconclusive laboratory results
Vaccine
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Vaccine product Age indications
MenACWY Vaccines
Menactra
MenACWY-D 9 months-55 years
Menveo
MenACWY-CRM 2months–55 years
MenB Vaccines
Trumemba
MenB-FHbp 10-25 years 
Bexsero
Men B-4C 10-25 years 
 Meningococcal polysaccharide conjugated to protein carrier
 Elicit both T- and B-cell immunity (T-cell dependent immunity)
 2 brands currently licensed in the United States
– Menactra = MenACWY-D (Sanofi Pasteur)
– Menveo = MenACWY-CRM (Novartis)
Meningococcal Conjugate Vaccines
 Licensed by FDA in January 2005
 Quadrivalent polysaccharide vaccine conjugated to diphtheria toxoid 
(MenACWY-D)
 Approved for persons 9 months through 55 years of age
 Intramuscular injection
 Single dose vials
Menactra MenACWY Vaccine
 Licensed by FDA in February 2010
 Lyophilized serogroup A vaccine reconstituted with liquid containing 
serogroups C, Y, and W135 (MenACWY-CRM)
 May be used for any person 2 months through 55 years of age for whom 
MCV4 is indicated, including revaccination
 Intermuscular injection
 Single dose vials
Menveo MenACWY Vaccine
 Limited data suggest that different conjugate vaccine products can be used 
interchangeably. 
 Whenever feasible, the same brand of vaccine should be used for all doses of the 
vaccination series
 If vaccination providers do not know or have available the type of vaccine product 
previously administered, any product should be used to continue or complete the 
series
Interchangeability of Conjugate Vaccine Brands
MMWR 2013;62(RR-2):10-11
Clinical 
Considerations
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 Child and adolescent immunization schedule 
 Adult immunization schedule 
MenACWY Recommendations
 Administer MenACWY at age 11 or 12 years with a booster dose at 16 years of age
 Administer 1 dose at age 13 through 15 years if not previously vaccinated
 For persons vaccinated at age 13 through 15 years, administer a one-time booster 
dose, preferably at or after 16 through 18 years of age
– The minimum interval between doses is  8 weeks
MenACWY Recommendations
 A booster dose is not recommended for healthy persons if the first dose 
is administered at or after 16 years of age
 A booster dose is not recommended for healthy persons after 21 years of 
age who are not at increased risk of exposure
– A booster dose is not recommended for healthy persons 22 years of age and  older 
even if the first dose was administered at 11-15 years of age 
MenACWY Adolescent Vaccination Recommendations
MenACWY Vaccine Recommendations for 
Persons at Increased Risk for Meningococcal 
Disease
 Younger than 19 months
– Infant series at 2, 4, 6, and 12-15 months with MenACWY-CRM
 19-23 months who have not received a complete series
– 2-dose primary series of MenACWY-CRM 12 weeks** 
 24 months or older who have not received a complete series
– 2-dose primary series of either MenACWY 8-12 weeks  apart
High-risk Groups: Functional or Anatomic Asplenia or HIV 
Infection*
*Including sickle-cell disease
** Doses valid if 8 weeks apart  
 Children 2-18 months
– Infant series at 2, 4, 6, and 12-15 months with MenACWY-CRM; OR 
– 2-dose primary series of MenACWY-D starting at 9 months at least 12 weeks apart**
 19-23 months without complete series of either MenACWY
– 2-dose primary series of either MenACWY at least 12 weeks apart**
 24 months or older who have not received a complete series of either 
MenACWY
– 2-dose primary series of either MenACWY at least 12 weeks apart**
High-risk Groups: Persistent Complement Component 
Deficiency*
* Including persons taking Soliris (eculizumab)
** Doses valid if 8 weeks apart
 Persons who: 
– Are first-year college students aged ≤21 years living in residential housing 
– Travel to, or are residents of, countries where meningococcal disease is 
hyperendemic or epidemic 
– Are microbiologists routinely exposed to isolates of Neisseria meningitidis
– Military recruits
 Administer: 1 dose of MenACWY 
Meningococcal Vaccine Recommendations 
for Persons 2 through 55 years at High Risk 
 Person who receive primary immunization and remain at increased risk 
should receive booster doses 
– If primary immunization complete before 7 years of age:
• first booster should be 3 years after primary immunization and every 5 years 
thereafter if at continued risk
– If primary immunization complete on or after 7 years of age 
• first booster should be 5 years after primary immunization and every 5 years 
thereafter if at continued risk 
Meningococcal ACWY Vaccine Booster Doses
 Other high-risk persons recommended for  boosters:
– Microbiologists with prolonged exposure to Neisseria meningitidis
– Frequent travelers to or persons living in areas with high rates of meningococcal 
disease (see next slide)
 Revaccinate every 5 years as long as the person remains at increased 
risk
– MenACWY for persons 2 through 55 years of age
– MenACWY for persons 56 years and older also (off-label recommendation) if 
repeated vaccination anticipated
MenACWY Revaccination Recommendations
 International travelers should receive a booster dose of MenACWY if the 
last dose was administered 5 or more years previously
– Vaccination in the 3 years before the date of travel is required by the government 
of Saudi Arabia for all travelers to Mecca during the annual Hajj
International Travelers and Revaccination*
*CDC Travelers Health website at http://www.cdc.gov/travel 
 Meningococcal vaccines that are licensed for use in person aged ≥56 year are not 
currently available in the United States
 Persons aged ≥56 years who are recommended meningococcal vaccination because 
they are at increased risk for meningococcal disease should receive MenACWY
conjugate vaccine
– This includes, meningococcal vaccine-naïve persons aged ≥56 years who anticipate 
requiring only a single dose of meningococcal vaccine (e.g. travelers and persons at 
risk as a risk of a community outbreak)
– And persons who were vaccinated previously with MenACWY conjugate vaccine 
and are recommended for revaccination or for whom multiple doses are 
anticipated (e.g., person with asplenia, HIV, and microbiologists)
Updated Guidance for Use of Meningococcal Vaccines in 
Persons Aged ≥56 Years
MenACWY
Local reactions 11%-59%
Low-grade fever 5%-17%
Systemic reactions 
(headache, malaise, fatigue) 4%-54%
Meningococcal ACWY Adverse Reactions
MenB Vaccine Recommendations
Meningococcal B Vaccines 
Product Name 
(ACIP Abbreviation)
FDA Age 
Indications Schedule/Dosage/Route
Trumenba® 
(MenB-FHbp)
10 through 
25 years of age 
• 3-dose series 
- 0, 1–2, and 6-month 
OR
• 2-dose series
- 0, 6 month
• 0.5 mL dose 
• IM injection
Bexsero®
(MenB-4C)
10 through 
25 years of age 
• 2-dose
- 0, 1–6 month
• 0.5 mL dose
• IM injection 
 Recommendation for use in individuals ≥10 years of age at increased risk 
of disease
 Recommendation for use in adolescents and young adults not at 
increased risk for disease 
Meningococcal B Recommendations
 Certain persons aged ≥10 years* who are at increased risk for 
meningococcal disease should receive MenB vaccine. These persons 
include:
– Persons with persistent complement component deficiencies
– Persons with anatomic or functional asplenia**
– Microbiologists routinely exposed to isolates of Neisseria meningitides
– Persons identified as at increased risk because of a serogroup B meningococcal 
disease outbreak
ACIP MenB Recommendations
*ACIP off-label recommendation
**Including sickle cell disease
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a3.htm?s_cid=mm6422a3_w
 Certain other groups included in MenACWY (MCV4)recommendations 
for persons at increased risk, are not in this recommendation 
 MenB – NOT currently recommended for:
– Children aged 2 months – 9 years of age
– Persons who travel to or reside in countries where meningococcal disease is 
hyperendemic or epidemic because risk is generally not caused by serogroup B
– Routine use in first-year college students living in residence halls, military recruits, 
or all adolescents
ACIP MenB Recommendations
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a3.htm?s_cid=mm6422a3_w
 For persons at increased risk for meningococcal disease and for use 
during serogroup B outbreaks, 3 doses of MenB-FHbp should be 
administered at 0, 1-2, 6 months
 When given to healthy adolescents who are not at increased risk for 
meningococcal disease, 2 doses of MenB-FHbp should be administered 
at 0 and 6 months
Use of 2- and 3-Dose Schedules of MenB-FHbp (Trumenba) 
Meningococcal Serogroup B Vaccine
If a patient is recommended for 3 doses of Trumenba, 
but the second dose is delayed beyond a 6-month 
interval, a third dose is NOT necessary
If a patient is recommended for 2 doses of Trumenba, 
and the second dose is given less than 6 months after 
the first dose, then a repeat (3rd) dose must be 
administered 4 months after the second dose
Trumenba Timing and Spacing Errors
 Voted upon at the June 2019 ACIP 
meeting
 Will become official policy when 
published in MMWR
 Sign-up for email alerts!
Meningococcal B Vaccine Booster Doses
https://www.cdc.gov/vaccines/hcp/acip-recs/index.html
 A MenB vaccine series may be administered to adolescents and young 
adults aged 16–23 years to provide short-term protection against most 
strains of serogroup B meningococcal disease*
 The preferred age for MenB vaccination is 16–18 years
MenB for Adolescents and Young Adults
* Permissive recommendation (Category B)
MMWR October 23, 2015 / 64(41);1171-6
 MenB should be administered as either a 2-dose series of MenB-4C or a 
2-dose or 3-dose series of MenB-FHbp
 The same vaccine product should be used for all doses
 MenB-4C and MenB-FHbp may be administered concomitantly with 
other vaccines indicated for this age, but at a different anatomic site, if 
feasible
 No product preference to be stated
ACIP MenB Recommendations
 If a dose of MenB vaccine is administered and found to be a different 
brand from a dose previously administered:
– Pick the brand with which you want to continue the series
– Invalidate the dose of the other brand
– Continue the series
– Need a 4 week minimum interval from any invalid doses
– Need to follow the minimum intervals between doses of the chosen 
brand
MenB Vaccine Brand Error
Meningococcal B Adverse Reactions
Adverse Reactions
Pain at injection site, injection site 
reactions, erythema
28%-85%
fatigue, headache, chills, nausea, 
arthralgia
13%-60%
 Severe allergic reaction to vaccine component or following prior dose 
 Moderate or severe acute illness
Meningococcal Vaccine
Contraindications and Precautions
 MenACWY and MenB recommended for use in control of outbreaks caused by A, C, 
W, Y, or B 
 Outbreak definition: 
– at least 3 confirmed or probable primary cases of the same serogroup
– period of 3 months or less
– primary attack rate of more than 10 cases per 100,000 population 
Meningococcal Vaccine Use in Outbreaks
Resources
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 ACIP’s Meningococcal Recommendations web page
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html
 CDC’s Meningococcal Infection web page 
www.cdc.gov/meningococcal/index.html
 CDC’s Meningococcal Vaccination web page
www.cdc.gov/vaccines/vpd-vac/mening/default.htm
 Immunization Action Coalition Meningococcal web page
www.immunize.org/meningococcal/
 Children’s Hospital of Philadelphia Vaccine Education Center Meningococcal web 
page
http://www.chop.edu/centers-programs/vaccine-education-center/vaccine-
details/meningococcal-vaccine
Meningococcal Resources
